For some pharma dealmakers, corporate domiciles in Ireland have become hot commodities. The Irish tax code figured prominently in two recent biopharma buyout deals, and, as Bloomberg reports, this makes the biotech group Alkermes and Jazz Pharmaceuticals potential targets.
Analysts at GlobalData took a quarterly snapshot of the R&D expenses for a big batch of mid-cap biotechs and concluded that rising research costs were eroding corporate profitability. And they pinned the blame squarely on the pricey hunt for new cancer drugs.
Jazz Pharmaceuticals has stepped up to grab the worldwide rights to a tweaked version of the narcolepsy drug Xyrem from Lexington, MA-based Concert Pharmaceuticals, a biotech which has been making a splash with its deuterium-modification approach for next-gen therapeutics.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...
The Ireland-based drugmaker ($JAZZ) says it will shell out $650 million upfront and potentially $50 million more to scoop up Eusa Pharma and its drugs for cancer and critical care.
Just months after completing a merger with Azur Pharma, Jazz has picked up specialty drugmaker Eusa Pharma for up to $700 million.
The FDA has issued a stern warning to Jazz Pharmaceuticals ($JAZZ), saying the company failed to properly report serious side effects of its drugs. Jazz also failed to submit reports on 74 serious
Occasionally cited as a potential takeover target, Jazz Pharmaceuticals ($JAZZ) is in the news this morning with a takeover of its own. The biotech says it has struck an all-stock deal to acquire
The FDA has handed Jazz Pharmaceuticals a setback, spurning its application for a new therapy to treat fibromyalgia and sending the developer back to the drawing board for fresh data on JZP-6 that
An FDA advisory panel meeting Friday poured cold water on Jazz Pharmaceuticals' bid to market JZP-6 as a treatment for fibromyalgia as the drug contains a form of gamma hydroxybutyrate (GHB), the